For example, nivolumab is easy to cause endocrine adverse reactions; arthritis, pneumonia and liver adverse reactions are common in pembrolizumab therapy, domestic camrelizumab is easy to cause reactive skin capillarosis, and PD-L1 inhibitor atezolizumab is more likely to cause hypothyroidism, nausea, vomiting and other symptoms. Here, CD274 is linked to arthritic joint disease.